Thyroid Cancer Pipeline Insights Report 2024

February 28 10:40 2024
Thyroid Cancer Pipeline Insights Report 2024

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2024” report provides comprehensive insights about 40+ Thyroid Cancer companies and 40+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Thyroid Cancer Pipeline Report

  • DelveInsight’s Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
  • The leading companies working in the Thyroid Cancer Market include Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
  • Promising Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Trametinib and Dabrafenib. This is a global, multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
  • November 2023: Affylmmune Therapeutics Inc. announced a study of Phase 1 clinical trials for AIC100 CAR T Cells. The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
  • In July 2023, Eisai Limited announced a study of phase 1 & 2 clinical trials for Lenvatinib, Ifosfamide, and Etoposide. This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).
  • On January 2023, Famewave Ltd announced a study of phase 1 & 2 clinical trials for Nivolumab and Nal-IRI/5-FU/LV – Expansion. This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.

 

Request a sample and discover the recent advances in Thyroid Cancer Treatment Drugs @ Thyroid Cancer Pipeline Outlook Report

 

In the Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Thyroid Cancer Overview

Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one.

 

Find out more about Thyroid Cancer Therapeutics Assessment @ Thyroid Cancer Preclinical and Discovery Stage Products

 

Thyroid Cancer Emerging Drugs Profile

  • Donafenib: Suzhou Zelgen Biopharmaceuticals
  • Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Nivolumab: Bristol-Myers Squibb
  • RX208: Suzhou NeuPharma
  • AIC100: AffyImmune Therapeutics

 

Thyroid Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Thyroid Cancer therapies. The Thyroid Cancer companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.

 

Request a sample and discover the recent advances in Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Thyroid Cancer Segmentation

 

Thyroid Cancer Drugs and Companies

  • Rosiglitazone: Exelixis
  • Lenvatinib: Eisai Limited
  • Ifosfamide: Merck Sharp & Dohme LLC

 

Thyroid Cancer Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Thyroid Cancer Therapeutics Market include-

Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.

 

Dive deep into rich insights for drugs for Thyroid Cancer Pipeline, click here @ Thyroid Cancer Unmet Needs and Analyst Views

 

Scope of the Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Thyroid Cancer Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
  • Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Thyroid Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Thyroid Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Donafenib: Suzhou Zelgen Biopharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nivolumab: Bristol-Myers Squibb
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100: Affyimmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Thyroid Cancer Key Companies
  21. Thyroid Cancer Key Products
  22. Thyroid Cancer- Unmet Needs
  23. Thyroid Cancer- Market Drivers and Barriers
  24. Thyroid Cancer- Future Perspectives and Conclusion
  25. Thyroid Cancer Analyst Views
  26. Thyroid Cancer Key Companies
  27. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services